Mesalamine for prophylaxis of small bowel Crohn's disease recurrence
W M Bauer1, A Brzezinski, B A Lashner
1Center for Inflammatory Bowel Disease, Department of Gastroenterology/S40, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Abstract:
Mesalamine has been studied extensively as a therapeutic option in patients with Crohn's disease. Endoscopic follow-up of patients resected for ileal Crohn's disease has shown that, in the absence of treatment, postoperative recurrence occurs in approximately 70% to 90% of patients within 1 year of the operation. Recurrence requires further surgical intervention in approximately half of patients within 10 years. Therapeutic strategies aimed at preventing recurrence are essential to the management of patients with Crohn's disease. This article offers a critical evaluation of results from clinical studies of mesalamine for prevention of recurrence in small bowel Crohn's disease.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
